MA29735B1 - Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine - Google Patents

Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine

Info

Publication number
MA29735B1
MA29735B1 MA30631A MA30631A MA29735B1 MA 29735 B1 MA29735 B1 MA 29735B1 MA 30631 A MA30631 A MA 30631A MA 30631 A MA30631 A MA 30631A MA 29735 B1 MA29735 B1 MA 29735B1
Authority
MA
Morocco
Prior art keywords
inhibitor
tertbutoxyiminomethylcamptothecin
composition containing
microparticle composition
topoisomerase
Prior art date
Application number
MA30631A
Other languages
English (en)
Inventor
Isabel Ottinger
Oskar Kalb
Walter Stebler
Agnes Taillardat
Wolfgang Wirth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29735(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29735B1 publication Critical patent/MA29735B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES DE MICROPARTICULES DANS LESQUELLES LE PRINCIPE ACTIF EST UN INHIBITEUR DE LA TOPOISOMÉRASE 1, PLUS PARTICULIÈREMENT, LA 7-TERT-BUTOXYIMINOMETHYLCAMPTOTHÉCINE, PERMETTANT DE TRAITER ET DE PRÉVENIR DES MALADIES PROLIFÉRANTES PARMI LESQUELLES LE CANCER.
MA30631A 2005-08-10 2008-02-08 Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine MA29735B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
MA29735B1 true MA29735B1 (fr) 2008-09-01

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30631A MA29735B1 (fr) 2005-08-10 2008-02-08 Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine

Country Status (20)

Country Link
EP (1) EP1915132A1 (fr)
JP (1) JP2009504616A (fr)
KR (1) KR20080034989A (fr)
CN (1) CN101287448A (fr)
AR (1) AR055602A1 (fr)
AU (1) AU2006277879A1 (fr)
BR (1) BRPI0614757A2 (fr)
CA (1) CA2618084A1 (fr)
EC (1) ECSP088166A (fr)
GT (1) GT200600364A (fr)
IL (1) IL189076A0 (fr)
MA (1) MA29735B1 (fr)
MX (1) MX2008001965A (fr)
NO (1) NO20081213L (fr)
PE (1) PE20070232A1 (fr)
RU (1) RU2008108885A (fr)
TN (1) TNSN08062A1 (fr)
TW (1) TW200800195A (fr)
WO (1) WO2007017514A1 (fr)
ZA (1) ZA200800726B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (fr) 2024-03-04 2025-09-12 Debiopharm International S.A. Combinaison d'un inhibiteur de wee1 et d'un inhibiteur de topoisomérase 1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
GT200600364A (es) 2007-03-19
ZA200800726B (en) 2009-08-26
NO20081213L (no) 2008-05-13
AR055602A1 (es) 2007-08-29
TW200800195A (en) 2008-01-01
KR20080034989A (ko) 2008-04-22
CN101287448A (zh) 2008-10-15
PE20070232A1 (es) 2007-04-09
ECSP088166A (es) 2008-03-26
BRPI0614757A2 (pt) 2011-04-12
WO2007017514A1 (fr) 2007-02-15
AU2006277879A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
TNSN08062A1 (en) 2009-07-14
JP2009504616A (ja) 2009-02-05
MX2008001965A (es) 2008-03-26
CA2618084A1 (fr) 2007-02-15
EP1915132A1 (fr) 2008-04-30
RU2008108885A (ru) 2009-09-20

Similar Documents

Publication Publication Date Title
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
ECSP045429A (es) Combinacion de compuestos organicos
EP1754707A3 (fr) Composés multicycliques et leur utilisation comme inhibiteurs des enzymes PARP, VEGFR2 et MLK3
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
EA200800100A1 (ru) Соединения азаиндазола и способы применения
NO20082292L (no) Antiproliferativ kombinasjonsterapi ved anvendelse av visse platinumbaserte kjemoterapeutiske virekemiddel og EGFR inhibitorer eller pyrimidine analoger
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MA30982B1 (fr) Combinaison
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
MA35038B1 (fr) Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
WO2005117882A3 (fr) Derives d'acide hydroxamique en tant qu'inhibiteurs de metalloproteases
MA29735B1 (fr) Composition de microparticules contenant un inhibiteur de la topoisomerase 1, la 7-tert-butoxyiminomethylcamptothecine
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
UY29240A1 (es) Nuevos derivados de piridotienopirimidina
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
WO2007017513A3 (fr) Formulations pour 7-(t-butoxy)iminomethyl camptothecine
TW200719903A (en) Compositions for the treatment of neoplasms
ATE457727T1 (de) Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen